Predicting blood-brain barrier permeation from three-dimensional molecular structure

被引:385
作者
Crivori, P
Cruciani, G
Carrupt, PA
Testa, B
机构
[1] Univ Perugia, Lab Chemomet, I-06123 Perugia, Italy
[2] Univ Lausanne, Inst Med Chem, BEP, CH-1015 Lausanne, Switzerland
关键词
D O I
10.1021/jm990968+
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Predicting blood-brain barrier (BBB) permeation remains a challenge in drug design. Since it is impossible to determine experimentally the BBB partitioning of large numbers of preclinical candidates, alternative evaluation methods based on computerized models are desirable. The present study was conducted to demonstrate the value of descriptors derived from 3D molecular fields in estimating the BBB permeation of a large set of compounds and to produce a simple mathematical model suitable for external prediction. The method used (VolSurf) transforms 3D fields into descriptors and correlates them to the experimental permeation by a discriminant partial least squares procedure. The model obtained here correctly predicts more than 90% of the BBB permeation data. By quantifying the favorable and unfavorable contributions of physicochemical and structural properties, it also offers valuable insights for drug design, pharmacological profiling, and screening. The computational procedure is fully automated and quite fast. The method thus appears as a valuable new tool in virtual screening where selection or prioritization of candidates is required from large collections of compounds.
引用
收藏
页码:2204 / 2216
页数:13
相关论文
共 54 条
  • [1] AASMUNDSTAD TA, 1995, J PHARMACOL EXP THER, V275, P435
  • [2] HYDROGEN-BONDING .33. FACTORS THAT INFLUENCE THE DISTRIBUTION OF SOLUTES BETWEEN BLOOD AND BRAIN
    ABRAHAM, MH
    CHADHA, HS
    MITCHELL, RC
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (09) : 1257 - 1268
  • [3] Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?
    Ajay
    Walters, WP
    Murcko, MA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3314 - 3324
  • [4] [Anonymous], SYBYL
  • [5] BABE SK, 1996, GOODMAN GILMANS PHAR, P581
  • [6] Predicting blood-brain transport of drugs: A computational approach
    Basak, SC
    Gute, BD
    Drewes, LR
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (05) : 775 - 778
  • [7] Stereoselective passage of mefloquine through the blood-brain barrier in the rat
    Baudry, S
    Pham, YT
    Baune, B
    Vidrequin, S
    Crevoisier, C
    Gimenez, F
    Farinotti, R
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (11) : 1086 - 1090
  • [8] BOBBYER DNA, 1989, J MED CHEM, V32, P1083
  • [9] PHARMACOLOGICAL STUDIES WITH SK AND F-93944 (TEMELASTINE), A NOVEL HISTAMINE H-1-RECEPTOR ANTAGONIST WITH NEGLIGIBLE ABILITY TO PENETRATE THE CENTRAL-NERVOUS-SYSTEM
    BROWN, EA
    GRIFFITHS, R
    HARVEY, CA
    OWEN, DAA
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1986, 87 (03) : 569 - 578
  • [10] ZOLANTIDINE (SK-AND-F-95282) IS A POTENT SELECTIVE BRAIN-PENETRATING HISTAMINE H-2-RECEPTOR ANTAGONIST
    CALCUTT, CR
    GANELLIN, CR
    GRIFFITHS, R
    LEIGH, BK
    MAGUIRE, JP
    MITCHELL, RC
    MYLEK, ME
    PARSONS, ME
    SMITH, IR
    YOUNG, RC
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1988, 93 (01) : 69 - 78